Article
[A Real-world Study on the Expression Characteristics of PD-L1 in Patients with Advanced EGFR Positive NSCLC and Its Relationship with the Therapeutic Efficacy of EGFR-TKIs].
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Mar 2023
Chen Ran, Gao Xiang, Xu Fudong, Zhang Shucai, Ma Li, Hu Bo
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is the first choice for first-line treatment of advanced patients with EGFR positive non-small cell lung cancer (NSCLC). For advanced NSCLC patients with negative drive gene and positive programmed cell death ligand 1 (PD-L1) or highly expressed NSCLC patients, the first-line treatment recommends immune checkpoint inhibitors...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.